<DOC>
	<DOCNO>NCT01228019</DOCNO>
	<brief_summary>This survey conduct assess safety efficacy niacin ( + ) laropiprant ( TREDAPTIVE ) usual practice Korea accord new product re-examination regulation Korean Food Drug Administration .</brief_summary>
	<brief_title>Niacin ( + ) Laropiprant ( TREDAPTIVE ) Re-examination Study ( MK-0524A-119 )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Participants treat TREDAPTIVE tablet within current local label first time Participants primary hypercholesterolemia mixed dyslipidemia Participants treat TREDAPTIVE equal 24 week include longterm surveillance Special participant know hepatic disorder renal disorder , participants 65 year old old , participant young 19 year old , pregnant woman evaluate collect . Participant treat TREDAPTIVE tablet contract enrollment period Participant contraindication TREDAPTIVE tablet accord current local label</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Usual practice re-examination</keyword>
</DOC>